原发性血小板增多症和真性红细胞增多症中未满足的需求。

Unmet Need in Essential Thrombocythemia and Polycythemia Vera.

作者信息

Kishtagari Ashwin, Gerds Aaron T

机构信息

Leukemia & Myeloid Disorders Program, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, CA60, Cleveland, OH 44120, USA.

出版信息

Hematol Oncol Clin North Am. 2021 Apr;35(2):295-303. doi: 10.1016/j.hoc.2021.01.003. Epub 2021 Feb 3.

DOI:10.1016/j.hoc.2021.01.003

PMID:33641870

Abstract

Consensus guidelines have helped to standardize the care of patients with essential thrombocythemia and polycythemia vera, focusing on reducing the risk of thrombosis, mitigating symptoms, and avoiding therapies that may accelerate disease progression. However, many unmet needs still exist ranging from the roll of antiplatelet therapy in ET to medications that reduce disease progression. Retrospective studies suggest an improvement in myelofibrosis-free survival for treatment with interferons; new agents are looking to also enact disease modification.

摘要

共识指南有助于规范原发性血小板增多症和真性红细胞增多症患者的护理，重点是降低血栓形成风险、缓解症状以及避免可能加速疾病进展的治疗方法。然而，从抗血小板治疗在原发性血小板增多症中的作用到降低疾病进展的药物，仍存在许多未满足的需求。回顾性研究表明，干扰素治疗可改善无骨髓纤维化生存期；新型药物也有望实现疾病改善。